Design, synthesis, and biological evaluation of dithiocarbamate derivatives as SARS-CoV-2 M^pro inhibitors

Area of Science:

• Drug Discovery and Development
• Virology
• Medicinal Chemistry

Background:

• The SARS-CoV-2 main protease (M^pro) is crucial for viral replication and maturation.
• M^pro is a highly conserved enzyme with no human homologues, making it an attractive drug target.
• Ongoing viral mutations necessitate the development of novel antiviral therapies.

Purpose of the Study:

• To design and synthesize novel dithiocarbamate derivatives as potential inhibitors of SARS-CoV-2 M^pro.
• To evaluate the inhibitory activity of these compounds against SARS-CoV-2 M^pro.
• To identify lead compounds for further development as anti-coronaviral therapeutics.

Main Methods:

• Chemical synthesis of a series of dithiocarbamate derivatives.
• Biochemical assays to determine the inhibitory concentration (IC₅₀) against SARS-CoV-2 M^pro.
• Structure-activity relationship analysis of the synthesized compounds.

Main Results:

• Several dithiocarbamate derivatives demonstrated potent inhibition of SARS-CoV-2 M^pro.
• Compound L2 exhibited a low IC₅₀ value of 9.1 ± 2.0 nM against SARS-CoV-2 M^pro.
• The results highlight the efficacy of dithiocarbamate scaffold in targeting viral proteases.

Conclusions:

• Dithiocarbamate derivatives represent a promising class of compounds for targeting SARS-CoV-2 M^pro.
• Compound L2 is a potent inhibitor and a potential candidate for anti-coronaviral drug development.
• Further research is warranted to explore the therapeutic potential of these inhibitors.